The Importance of Antihypertensive and Lipid-Lowering Therapy in the Treatment of Patients with a New Coronavirus Infection COVID-19
https://doi.org/10.20996/1819-6446-2021-03-01
Abstract
At the end of 2020, a new term “post-COVID-19 syndrome” appeared in the medical community. The prevalence of this syndrome reaches more than 30% among patients who have had COVID-19, and its duration can vary from 12 weeks to 6 months. One of the most severe consequences of COVID- 19 is the defeat of the cardiovascular system, which has a variety of mechanisms: dysregulation of the renin-angiotensin-aldosterone system; pathological systemic inflammatory response; direct action of the virus on the myocardium with the development of myocarditis; respiratory failure with hypoxia, leading to damage to cardiomyocytes; microvascular damage due to hypoperfusion, increased vascular permeability, angiospasm and the direct damaging effect of the virus on the endothelium of the coronary arteries; thrombotic complications due to the procoagulant and prothrombogenic effect of systemic inflammation. One of the most promising directions in the treatment and prevention of damage to the cardiovascular system in patients with hypertension who have undergone COVID-19 is the appointment of antihypertensive drugs that have the most pronounced organoprotective properties together with statins. The single pill combination of lisinopril, amlodipine and rosuvastatin is an effective drug that allows achieving not only adequate hypotensive and lipid-lowering effects, but also due to its pronounced organoprotective properties, to expect a reduction in cardiovascular risk and complications in patients who have suffered a new coronavirus infection caused by the SARS-CoV-2 virus.
About the Authors
V. I. Podzolkov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Russian Federation
Russian Federation
Valery I. Podzolkov - eLibrary SPIN 8683-2155
Moscow
A. I. Tarzimanova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Russian Federation
Russian Federation
Aida I. Tarzimanova - eLibrary SPIN 2685-4078
Moscow
References
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. DOI:10.1016/S0140-6736(20)30183-5
2. Grinevich VB, Gubonina IV, Doshchitsin VL, et al. Features of the management of comorbid patients during a pandemic of a new coronavirus infection (COVID-19). National Consensus 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630 (In Russ.) DOI:10.15829/1728-8800-2020-2630
3. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic [cited by Mar 01, 2021]. Available from: https://www.escardio.org/Education/COVID-19-and-Cardiol-ogy/ESC-COVID-19-Guidance.
4. Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801 (In Russ.). DOI:10.15829/1560-4071-2020-3-3801.
5. Barker-Davies RM, O'Sullivan O, Senaratne KPP, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020;54(16):949-59. DOI:10.1136/bjsports-2020-102596.
6. Goёrtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-2020. DOI:10.1183/23120541.00542-2020.
7. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. DOI:10.1177/1470320320926899.
8. Lo KB, Bhargav R, Salacup G, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2020;18(12):919-30. DOI:10.1080/14779072.2020.1826308.
9. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (In Russ.)
10. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012;205:13-9. DOI:10.1093/infdis/jir695.
11. Reiner Z, Hatamipour M, Banach M, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490-6. DOI:10.5114/aoms.2020.94655.
12. Daniels LB, Sitapati AM, Zhang J, et al. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol. 2020:S0002-9149(20)30947-4. DOI:10.1016/j.amjcard.2020.09.012.
13. Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther. 2004;26(6):855-65. DOI:10.1016/s0149-2918(04)90129-4.
14. Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997;30(1 Pt 1):140-5. DOI:10.1161/01.hyp.30.1.140.
15. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation. 1997;95(6);1464-70. DOI:10.1161/01.cir.95.6.1464.
16. Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303-9. DOI:10.1097/00004872-200102000-00018.
17. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349(9068):1787-92. DOI:10.1016/S0140-6736(96)10244-0.
18. Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells. 2020;9(7):1652. DOI:10.3390/cells9071652.
19. Hernandez RH, Armas-Hernandez MJ, Velasco M. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther. 2003;10(6):409-14. DOI:10.1097/00045391-200311000-00006.
20. Jоrgensen B, Thaulow E. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Am Heart J. 2003;145(6):1030-5. DOI:10.1016/S0002-8703(03)00082-6.
21. Nissen SE, Tuzcu EM, Libby P, et al., CAMELOT Investigators. Effect of antihypertensive agents on cardiorprovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-25. DOI:10.1001/jama.292.18.2217.
22. Laufs U, Gertz K, Dirnagl U, et al. Rosuvastatin, a new-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice. Brain Res. 2002;942(1-2):23- 30. DOI:10.1016/s0006-8993(02)02649-5.
23. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. DOI: 10.1056/NEJ-Moa0807646.
24. Underhill H, Yuan C, Zhao X, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008;155(3):584 e1-e8. DOI:10.1016/j.ahj.2007.11.018.
25. Nissen S, Stephen J, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295:1556-65. DOI:10.1001/jama.295.13.jpc60002.
26. Blankova ZN, Aslanyan NS. The effect of combination therapy on the state of the vascular wall in patients with high cardiovascular risk. Systemic Hypertension. 2017;14(2):51-5 (In Russ.) DOI:10.26442/2075-082X_14.2.51-55.
Review
For citations:
Podzolkov V.I., Tarzimanova A.I. The Importance of Antihypertensive and Lipid-Lowering Therapy in the Treatment of Patients with a New Coronavirus Infection COVID-19. Rational Pharmacotherapy in Cardiology. 2021;17(2):310-314. (In Russ.) https://doi.org/10.20996/1819-6446-2021-03-01
Views:
670
.jpg)
Email this article 